Last reviewed · How we verify

NCT05709990

Efficacy and Safety of High Dose Vitamin D Supplementation for Overactive Bladder Dry in Children

Completed NA Last updated 6 February 2024
What this trial tests

NA trial testing Solifenacin Succinate 5 MG Oral Tablet [Vesicare] in Overactive Bladder in 303 participants. Completed in 15 June 2023.

Timeline
15 January 2023
Primary endpoint
3 June 2023
15 June 2023

Quick facts

Lead sponsorXing Liu
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment303
Start date15 January 2023
Primary completion3 June 2023
Estimated completion15 June 2023
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Xing Liu — full company profile →

Who can join

Adults 5 to 18, any sex, with Overactive Bladder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This prospective, randomized, 3-arms, parallel-design, controlled clinical trial is conducted to determine whether high dose vitamin D supplementation (combined with standard urotherapy ) improves outcomes, compared with solifenacin (combined with standard urotherapy ) ,and standard urotherapy alone in children with OAB dry.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Overactive Bladder

Currently open trials in the same condition.

Other Xing Liu trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05709990.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing